Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
Cave B, Hough A, Dobesh PP.
Pharmacotherapy · review; journal article · DOI 10.1002/phar.2102 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för betrixaban. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
35 träffar2018 New Drug Update.
Hussar DA, Finn LA.
Consult Pharm · journal article · DOI 10.4140/tcp.n.2018.188Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No.
Marongiu F, Barcellona D.
Intern Emerg Med · journal article · DOI 10.1007/s11739-018-1843-9Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment.
Al Yami MS, Kurdi S, Abraham I.
J Blood Med · research-article; journal article · DOI 10.2147/jbm.s149202Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor.
Skelley JW, Thomason AR, Nolen JC, Candidate P.
P T · other; journal articleBetrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Garland SG, DeRemer CE, Smith SM, Gums JG.
Ann Pharmacother · systematic review; journal article · DOI 10.1177/1060028018754383Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM.
J Thromb Thrombolysis · comparative study; randomized controlled trial; journal article · DOI 10.1007/s11239-017-1583-0Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM.
Circulation · letter; comparative study; research support, non-u.s. gov't; randomized controlled trial · DOI 10.1161/circulationaha.117.031187Betrixaban (Bevyxxa) for VTE prophylaxis in acute medical illness.
Författaruppgift saknas
Med Lett Drugs Ther · journal articleUpdate on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.
Jacobs A, Kabra R, Das P, Oliphant CS.
Future Cardiol · journal article · DOI 10.2217/fca-2017-0045Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
Chi G, Goldhaber SZ, Hull RD, Hernandez AF, Kerneis M, Al Khalfan F, Cohen AT, Harrington RA, Gibson CM.
Thromb Haemost · clinical trial; journal article · DOI 10.1160/th17-08-0538Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE, Burnett AE, Fletcher ML, Spyropoulos AC.
Hosp Pract (1995) · review; journal article · DOI 10.1080/21548331.2018.1410053Formulary Drug Review: Betrixaban.
Baker DE.
Hosp Pharm · review-article; review; journal article · DOI 10.1177/0018578717739397Betrixaban, sofosbuvir/velpatasvir/voxilaprevir, and glecaprevir/pibrentasvir.
Hussar DA, Inman B.
J Am Pharm Assoc (2003) · journal article · DOI 10.1016/j.japh.2017.10.002Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Arbetter DF, Jain P, Yee MK, Michalak N, Hernandez AF, Hull RD, Goldhaber SZ, Harrington RA, Gold A, Cohen AT, Gibson CM.
Pharm Stat · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/pst.1823Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.
Ageno W.
Intern Emerg Med · review; journal article · DOI 10.1007/s11739-017-1723-8Betrixaban approved as oral VTE preventive.
Traynor K.
Am J Health Syst Pharm · journal article · DOI 10.2146/news170047Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Escolar G, Díaz-Ricart M, Arellano-Rodrigo E.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2017.53.8.2681448Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA, APEX Investigators.
J Am Heart Assoc · clinical trial, phase iii; comparative study; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1161/jaha.117.006015The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis.
Marszalek J, Mehrsefat S, Chi G.
Expert Rev Hematol · journal article · DOI 10.1080/17474086.2017.1343662Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?
Quinlan DJ, Eikelboom JW, Hart RG.
Circulation · comment; editorial · DOI 10.1161/circulationaha.116.026170The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT, APEX Investigators.
Am Heart J · comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ahj.2016.12.004Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?
Ramacciotti E, Hoppensteadt D, Fareed J.
Clin Appl Thromb Hemost · letter · DOI 10.1177/1076029616683805Betrixaban in Acutely Ill Medical Patients.
Cohen AT, Harrington RA, Gibson CM.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1613217Betrixaban in Acutely Ill Medical Patients.
Patil R, Ghosh K, Shetty S.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1613217Betrixaban in Acutely Ill Medical Patients.
Kakkos SK, Nikolakopoulos K, Tsolakis IA.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1613217Betrixaban in Acutely Ill Medical Patients.
Cave B, Hough A, Rosenstein R.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1613217Betrixaban - the next direct factor Xa inhibitor?
Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C.
Expert Rev Hematol · review; journal article · DOI 10.1080/17474086.2016.1256194Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT, APEX Investigators.
Circulation · research support, non-u.s. gov't; journal article · DOI 10.1161/circulationaha.116.025427[Betrixaban reduces tromboembolic events].
Schinzel H.
Dtsch Med Wochenschr · controlled clinical trial; journal article · DOI 10.1055/s-0042-117367